ERBB2 S1050L

CI-VAR-00003974Explore in graph →CIViC 3497

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
ERBB2 S1050L	Afatinib + Cetuximab + ErlotinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID9680 In an in vitro study, a head and neck squamous cell carcinoma cell line OSC-19 expressing ERBB2 (HER2) S1050L mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib treatment… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.